Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Winnacunnet High School senior Joe Labrecque has transformed his battle with a rare chronic illness into a mission to help others.

Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

Aside from Myasthenia Gravis, Telitacicept has been approved in China for the treatment of two other major indications, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

A Johnson & Johnson autoimmune disease medicine that ... as a treatment for generalized myasthenia gravis (gMG). The regulatory decision announced Wednesday could be the first of several for ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...

As such, UCB’s recently-debuted, U.S.-based DTC rare-disease campaign Imagine Your Zillions supports its gMG treatment Zilbrysq. The effort is based on flipping the preconceived notions associated ...

The US FDA has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder ...